Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Sci Rep ; 12(1): 15612, 2022 09 16.
Artigo em Inglês | MEDLINE | ID: mdl-36114224

RESUMO

Many therapeutic antibodies (Abs) and mRNA vaccines, both targeting SARS-CoV-2 spike protein (S-protein), have been developed and approved in order to combat the ongoing COVID-19 pandemic. In consideration of these developments, a common concern has been the potential for Ab-dependent enhancement (ADE) of infection caused by inoculated or induced Abs. Although the preventive and therapeutic effects of these Abs are obvious, little attention has been paid to the influence of the remaining and dwindling anti-S-protein Abs in vivo. Here, we demonstrate that certain monoclonal Abs (mAbs) approved as therapeutic neutralizing anti-S-protein mAbs for human usage have the potential to cause ADE in a narrow range of Ab concentrations. Although sera collected from mRNA-vaccinated individuals exhibited neutralizing activity, some sera gradually exhibited dominance of ADE activity in a time-dependent manner. None of the sera examined exhibited neutralizing activity against infection with the Omicron strain. Rather, some ADE of Omicron infection was observed in some sera. These results suggest the possible emergence of adverse effects caused by these Abs in addition to the therapeutic or preventive effect.


Assuntos
Anticorpos Facilitadores , Vacinas contra COVID-19 , COVID-19 , Soros Imunes , SARS-CoV-2 , Enzima de Conversão de Angiotensina 2 , Anticorpos Antivirais , COVID-19/imunologia , COVID-19/prevenção & controle , COVID-19/terapia , Vacinas contra COVID-19/imunologia , Humanos , Imunização Passiva , Pandemias , SARS-CoV-2/imunologia , Glicoproteína da Espícula de Coronavírus/imunologia , Soroterapia para COVID-19
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...